Immunotherapy

DLL3

• DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers

• DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers

• DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)

• Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

CAR T

• CHM-2101 CAR-T cell for GI Cancers

• IL13Rα2 CAR T Cell Study for Solid Tumor Cancers

Cancer Vaccine

• Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

Immune Checkpoint Inhibitor Combination Studies

• SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum

• Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

Oncolytic Virus

• SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)